4 hrs ago | AlertNet
Immune system cancer drugs tipped to be a $35 bln market
A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year.
Bristol-Myers Squibb Company is Fined for Monkey Deaths, but Will $2,600 Matter?
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In what is apparently an unusual move, the US Department of Agriculture earlier this year fined Bristol-Myers Squibb for violating the Animal Welfare Act after the deaths of two monkeys in its laboratories.
Teva Bets on Reformulating Drugs as Investors Say - Show Me'
Teva Pharmaceutical Industries Ltd., which just two years ago was analysts' highest-rated stock among the world's 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.
Bloomsbury Publishing Receives "Buy" Rating from Investec
's stock had its "buy" rating restated by equities researchers at Investec in a report issued on Tuesday, StocKRatingsNetwork.com reports.
Bristol Myers Squibb And The New Wave Of Cancer Drugs
Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.
FTSE 100 movers: RBS makes strong gains on Numis note
Royal Bank of Scotland was in the lead after Numis raised its target price from 308p to 410p, while upgrading the stock to buy.
Chinese pharma companies look West
Zhejiang Hisun Pharmaceutical Co's pavilion at a fair in Beijing. By setting up a joint venture with US-based Pfizer Inc in September, Hisun made a breakthrough in China's pharmaceutical industry by taking a controlling stake in the JV with Pfizer, the world's largest drug-maker by sales.
Bristol-Myers Squibb drug study showed effectiveness against advanced melanoma cancer
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Bristol-Myers Drug Cocktail Quells Melanoma Tumors, Study Finds
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Bristol-Myers shares jump ahead of melanoma trial data
Bristol-Myers shares were up 5.1 percent at $44.35 shortly before the close on Wednesday, in their busiest day of trading since August.
Bristol-Myers Squibb: The Caped Crusaders
Bristol-Myers Squibb's Joseph Campisi and Demetrios Kyonieus were virtually inseparable for eight months in 2012 while they negotiated an M&A deal that was large and complex.
Bristol-Myers Squibb to Present at UBS Global Health Care Conference
Bristol-Myers Squibb Company will present at the UBS Global Health Care Conference on Tuesday, May 21, 2013, in New York City.
Should You Buy Stock in Gilead After the Earnings Miss?
The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... ) reported a relatively rare earnings miss in the first quarter on May 2. The biotech announced earnings of $0.48 per share while analysts were expecting $0.50 per share.
Midday Market Stats: Dow Jones Industrial Average, S&P 500 Jump to Record Intraday Peaks
The Dow Jones Industrial Average is up 74 points, or 0.5%, to 15,165.81 , boosted by positive comments made by David Tepper this morning.
Bristol-Myers Squibb Co. v. Genentech, Inc. et al. 3:13-cv-02045; filed May 3, 2013 in the Northern District of California Declaratory judgment of invalidity, unenforceability, and noninfringement of of U.S. Patent Nos.
Marshall is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Research and Markets: Bristol-Myers Squibb Partnering 2005-2013
This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years.
Bas Burger To Lead BT Operations In The US & Canada And Across Global Industry Sectors
BT announced the appointment of Bas Burger to the position of president of BT US & Canada and president for the Global Consumer Packaged Goods and the Global Pharmaceutical and Chemical industry sectors.
Customer Interaction Solutions
RBCC Partner n3D Signs U.S. Distribution Agreement
Rainbow Coral Corp. received word this week that the revolutionary technology developed by its partner, Nano3D Biosciences , is set to begin penetrating the U.S. marketplace.
Immune-Boosting Cancer Drugs Seen Extending Lives Along With Sales: Health
Merck & Co. , Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.